Related Experiment Video
Updated: May 8, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rapid rituximab infusion, local center experience.
E A Monem1, B Al-Bahrani, I Mehdi
1Essam Abdul Monem, Department of Medical Oncology, National Cancer Center, Royal Hospital, Muscat, Sultanate of Oman. Tel: 968 92575280 Fax: 968 24627045
The Gulf Journal of Oncology
|September 3, 2013
Summary
Rapid rituximab infusions are safe and well-tolerated for Non-Hodgkin
Area of Science:
- Oncology
- Immunology
Background:
- Rituximab is a monoclonal antibody targeting CD20, used for B-cell lymphoproliferative disorders.
- Standard rituximab infusion (3-4 hours) is resource-intensive and inconvenient.
- Previous reports suggest rapid rituximab infusion is feasible and safe.
Purpose of the Study:
- To evaluate the safety and tolerability of shortened rituximab infusion.
- To assess the feasibility of rapid rituximab administration in clinical practice.
Main Methods:
- 24 patients with CD20+ Non-Hodgkin's lymphoma received rituximab (375mg/m2) with chemotherapy.
- First dose administered over 3-4 hours; subsequent doses over 90 minutes.
- Infusion-related toxicity was monitored.
Main Results:
- 152 rituximab infusions were administered (average 6.33 per patient).
- Grade 1 infusion-related toxicity occurred in 3.2% of infusions.
- No acute reactions or Grade 3/4 toxicity were observed.
Conclusions:
- Shortened rituximab infusion (90 minutes) is safe and well-tolerated for subsequent doses.
- This method reduces healthcare resource utilization.
- The institution adopted rapid infusion as routine practice.
